Sugi Predict

Sugi Predict / Compounds / SCHEMBL535883

SCHEMBL535883

SCHEMBL535883

CCOC(=O)C(C)(C)C#N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ ALDH1A1 P00352 3/20 0.47
▸ TSHR P16473 2/20 0.47
▸ CYP4F2 P78329 3/20 0.41
▸ CYP4A11 Q02928 3/20 0.41
▸ PKM P14618 3/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ THRB P10828 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ MGAM O43451 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SI P14410 1/20 0.37
▸ MGAM2 Q2M2H8 1/20 0.37
▸ SOAT1 P35610 1/20 0.37
▸ ABCB11 O95342 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7565591 0.82 MEN1 (0.52) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL28164782 0.82 MEN1 (0.52) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL28001819 0.79 MEN1 (0.46) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL7065729 0.79 MEN1 (0.44) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL28836686 0.78 MEN1 (0.48) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL28242892 0.78 MEN1 (0.53) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL3248205 0.78 MEN1 (0.48) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL15858335 0.78 MEN1 (0.53) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL28242894 0.78 MEN1 (0.53) MEN1KMT2AALDH1A1TSHRCYP4F2
Ethane SCHEMBL20528159 0.77 MEN1 (0.52) MEN1KMT2AALDH1A1TSHRCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117466938-A Luminescent material, ink composition and display panel 广州华星光电半导体显示技术有限公司 2024-01-30 — — CN claimed
US-8759580-B2 Method for the production of aminoalkane acid amides BASF SE (DE) 2014-06-24 — — US claimed
US-12583858-B2 TDO2 inhibitors GENENTECH, INC. (US) 2026-03-24 — — US disclosed
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases ONCO3R THERAPEUTICS BV (BE) 2025-08-19 — — US disclosed
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-04-10 — — US disclosed
CN-113924146-B Novel compounds and pharmaceutical compositions thereof for the treatment of diseases 加拉帕戈斯股份有限公司 2024-12-10 — — CN disclosed
CN-119053588-A P38 alpha-MK 2 inhibitor compound, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2024-11-29 — — CN disclosed
EP-3394068-B1 TDO2 INHIBITORS GENENTECH INC (US) 2024-09-11 — — EP disclosed
EP-3976189-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2024-07-03 — — EP disclosed
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 — — EP disclosed
CN-118076607-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2024-05-24 — — CN disclosed
EP-0600950-B1 AMIDE TETRAZOLE ACAT INHIBITORS WARNER LAMBERT CO (US) 1996-10-23 — — EP disclosed
EP-0684945-A1 HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1995-12-06 — — EP disclosed
US-5441975-A Anticholesterol agent WARNER-LAMBERT COMPANY (US) 1995-08-15 — — US disclosed
US-5366987-A Enzyme inhibitors, anticholesterol WARNER-LAMBERT COMPANY (US) 1994-11-22 — — US disclosed
WO-1994019330-A1 HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1994-09-01 — — WO disclosed
EP-0600950-A1 AMIDE TETRAZOLE ACAT INHIBITORS. WARNER LAMBERT CO (US) 1994-06-15 — — EP disclosed
WO-1993004052-A1 AMIDE TETRAZOLE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1993-03-04 — — WO disclosed
US-4141915-A REACTING AN UNSATURATED NITRILE, AN ALCOHOL, AND CARBON MONOXIDE DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1979-02-27 — — US disclosed
US-4024272-A Tetracyclic compounds MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583858-B2 TDO2 inhibitors TDO2, IDO2, TPH2 MEN1 4820/4885KMT2A 2433/4885ALDH1A1 1758/4885
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 MEN1 3403/4885KMT2A 1840/4885ALDH1A1 4008/4885
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases IL5, IL15, IL1A MEN1 2969/4885KMT2A 2812/4885ALDH1A1 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.